PROLASTIN DIRECT PROGRAM

One source for the needs of every patient with alpha-1

When you prescribe PROLASTIN®-C LIQUID, your patients gain immediate access to all the benefits of the PROLASTIN DIRECT program. PROLASTIN-C LIQUID is available only through the PROLASTIN DIRECT program.


 

To help you get started, speak with a Patient Service Coordinator by calling 1-833-PHONEA1 (746-6321).

Enroll a Patient

* AlphaNet is a registered trademark of AlphaNet, Inc.

PROLASTIN DIRECT provides support
beyond treatment

Designed to make treatment management easier for patients.

Specialty Pharmacy Hub Personalized Onboarding Support

Support from nurse navigators, pharmacists, and program managers focused on alpha-1 help ensure a smooth start to care, with coordination of infusions at home or approved facilities based on patient and provider preferences.1

Insurance and Access Assistance

Insurance and reimbursement specialists focused solely on alpha-1 provide dedicated support with prior authorization, insurance documentation, and appeals, along with 24/7 on-call assistance from registered nurses and pharmacists specializing in alpha-1 care.1

Financial Support and Affordability

$0 copay with the Grifols Assist program for eligible patients, offering up to $10,000 in annual financial support that can be applied to deductibles, copayments, and coinsurance for 
PROLASTIN-C LIQUID.1

Supporting patients leads to better outcomes

Through PROLASTIN DIRECT, patients are automatically enrolled in the AlphaNet Alpha-1 Disease Management and Prevention Program (ADMAPP), which provides one-on-one support from a trained patient with alpha-1 who fully understands their condition.2

Health Outcomes Study Results (N=878)3†

Significant improvements in compliance with therapy‡

  • Participants were members of AlphaNet, a not-for-profit health management company founded by people with alpha-1 to provide comprehensive care solely for people with alpha-13
  • 97% of ADMAPP study participants were taking PROLASTIN-C LIQUID3

† 2-year study comparing outcomes in a 12-month observation period with augmentation therapy alone followed by a 12-month intervention period with augmentation therapy plus ADMAPP.3
‡ 10% increase in compliance with long-term oxygen therapy use, and 15% increase in use of long-acting bronchodilators, which means more optimal medication use.3

Enrollment is easy

PROLASTIN DIRECT takes care of the rest while you and your practice can focus on managing your patients with alpha-1.

Download, Complete, and Fax

Download, complete, and fax the enrollment form for PROLASTIN DIRECT to 888-817-2098 to start the process.

Prescribe PROLASTIN-C LIQUID

For patients diagnosed with severe alpha-1 and clinical signs of emphysema.4

“When I connected with the PROLASTIN DIRECT program 
and AlphaNet, it was such a 
blessing for me.”

Toya Actual Patient Since 2016

“I get the support I need with PROLASTIN DIRECT.”

Heather Actual Patient Since 2018

“I’m very impressed with the PROLASTIN DIRECT program. As a provider, it allows office visits to be truly patient-focused, not paperwork-driven.”

Corinne Young Healthcare Provider
 
 

Support your patients LIKE A PRO
with PROLASTIN DIRECT®

PROLASTIN-C LIQUID is available through the PROLASTIN DIRECT program.

Enroll Patients

Frequently asked questions

PROLASTIN DIRECT is a patient support program designed to simplify treatment management for those prescribed PROLASTIN-C LIQUID. It provides personalized onboarding, coordination of care, insurance and access assistance, and financial support for eligible patients through the Grifols Assist program.

Enrollment is easy. Download, complete, and fax the PROLASTIN DIRECT enrollment form to 888-817-2098. Once received, the program team will coordinate onboarding, insurance verification, and infusion scheduling to ensure a smooth start to therapy.

You can contact the PROLASTIN-C LIQUID team by calling 1-888-474-3657, emailing info@grifols.com, or filling out the online contact form to connect with a representative for program or enrollment support.

Important Safety Information

PROLASTIN®-C LIQUID is an alpha1-proteinase inhibitor (human) (alpha1-PI) indicated for chronic augmentation and maintenance therapy in adults with clinical evidence of emphysema due to severe hereditary deficiency of alpha1-PI (alpha1-antitrypsin deficiency). 


Limitations of Use

  • The effect of augmentation therapy with any alpha1-PI, including PROLASTIN-C LIQUID, on pulmonary exacerbations and on the progression of emphysema in alpha1-PI deficiency has not been conclusively demonstrated in randomized, controlled clinical trials.
  • Clinical data demonstrating the long-term effects of chronic augmentation or maintenance therapy with PROLASTIN-C LIQUID are not available.
  • PROLASTIN-C LIQUID is not indicated as therapy for lung disease in patients in whom severe alpha1-PI deficiency has not been established.

PROLASTIN-C LIQUID is contraindicated in immunoglobulin A (IgA)-deficient patients with antibodies against IgA or patients with a history of anaphylaxis or other severe systemic reaction to alpha1-PI products.

Hypersensitivity reactions, including anaphylaxis, may occur. Monitor vital signs and observe the patient carefully throughout the infusion. If hypersensitivity symptoms occur, promptly stop PROLASTIN-C LIQUID infusion and begin appropriate therapy.

Because PROLASTIN-C LIQUID is made from human plasma, it may carry a risk of transmitting infectious agents, eg, viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. This also applies to unknown or emerging viruses and other pathogens.

The most common adverse reactions during PROLASTIN-C LIQUID clinical trials in >5% of subjects were diarrhea and fatigue, each of which occurred in 2 subjects (6%).

Please see full Prescribing Information for PROLASTIN-C LIQUID.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

References

  1. Data on file, PROLASTIN DIRECT program, Grifols.
  2. Data on file, Grifols.
  3. Campos MA, Alazemi S, Zhang G, Wanner A, Sandhaus RA. Effects of a disease management program in individuals with alpha-1 antitrypsin deficiency. COPD. 2009;6(1):31–40.
  4. PROLASTIN®-C LIQUID (alpha1-proteinase inhibitor [human]) Prescribing Information. Grifols.